Lixte Biotechnology Holdings (DB:8640) - Aandelenkoers, Nieuws & Analyse

8640 Overzicht aandelen

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Meer informatie

8640 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 28.3% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( €6M )

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

+ 2 meer risico's

Lixte Biotechnology Holdings, Inc. Concurrenten

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

Medigene

XTRA:MDG1

€17.4m

4SC

DB:VSC

€50.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Lixte Biotechnology Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$0.63
52 Week Hoogtepunt	US$15.00
52 Week Laag	US$4.12
Bèta	-0.44
11 maand verandering	0%
3 maanden verandering	-89.75%
1 Jaar Verandering	-90.74%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-97.99%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	8640	DE Biotechs	DE Markt
7D	0%	-1.1%	1.1%
1Y	-90.7%	-18.8%	7.2%

Rendement versus industrie: 8640 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -18.8 % opleverde.

Rendement versus markt: 8640 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.2 % opleverde.

Prijsvolatiliteit

Is 8640's price volatile compared to industry and market?
8640 volatility
8640 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 8640 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 8640 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2005	4	John Kovach	lixte.com

Lixte Biotechnology Holdings, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Lixte Biotechnology Holdings zich tot de beurswaarde?
8640 fundamentele statistieken
Marktkapitalisatie	€5.24m
Inkomsten(TTM)	-€5.70m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.9x

Koers/Winstverhouding

Is 8640 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
8640 resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$6.15m
Inkomsten	-US$6.15m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.73
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 8640 op de lange termijn?

Bekijk historische prestaties en vergelijking

8640 Overzicht aandelen

Risicoanalyse

Lixte Biotechnology Holdings, Inc. Concurrenten

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

XTRA:MDG1

€17.4m

DB:VSC

€50.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Independent Director has left the company